In a recent interview with CEO.ca, Mark Upsdell, CEO of Rapid Dose Therapeutics (CSE: DOSE), discussed their game-changing QuickStrip technology that delivers medication “right into your bloodstream”. Their three-year development of nicotine strips targets the projected $20.3B non-smoking market by 2030, while also revolutionizing pain-free dentistry by potentially “eliminating the needle in lot of cases”.

You can read the full press release here:
https://www.newsfilecorp.com/release/259700

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

For more information about the Company, visit www.rapid-dose.com.

Contacts:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
416-477-1052